Raia Drogasil S.A. (OTCMKTS:RADLY – Get Free Report) shares saw unusually-strong trading volume on Friday . 232,871 shares traded hands during mid-day trading, an increase of 267% from the previous session’s volume of 63,460 shares.The stock last traded at $3.8566 and had previously closed at $4.00.
Raia Drogasil Price Performance
The business has a 50-day moving average price of $3.63 and a two-hundred day moving average price of $4.05.
Raia Drogasil (OTCMKTS:RADLY – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.05 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.05. The company had revenue of $2.17 billion during the quarter, compared to analyst estimates of $2.32 billion. As a group, sell-side analysts forecast that Raia Drogasil S.A. will post 0.17 EPS for the current year.
About Raia Drogasil
Raia Drogasil SA is a leading Brazilian retail pharmacy operator, offering a comprehensive range of prescription and over-the-counter medications, health and wellness products, personal care and beauty items, as well as a selection of convenience goods. The company’s network of stores operates under the Raia and Drogasil banners, serving diverse consumer needs across major urban centers. Complementary services include in-store prescription dispensing, compounding pharmacies and health screening programs such as blood pressure and glucose monitoring.
The company was formed in 2011 through the merger of two established Brazilian pharmacy chains, Drogasil and Droga Raia, each with origins dating back several decades.
Featured Stories
- Five stocks we like better than Raia Drogasil
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
- Snowflake’s AI Momentum Is Forcing a Fresh Look at the Stock
Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.
